Abstract

Introduction: The scope of complications arising after radiotherapy (RT) treatment for prostate cancer is underrecognized and not well-described. The objective of this study is to describe the presentation, scope, and management of genitourinary complications (GU) in patients referred for high-grade urethral complications or sphincter weakness incontinence after prostate RT.

Methods: A retrospective review was performed of patients referred to a reconstructive urologist for management of grade 4 urethral complications and sphincter weakness incontinence after prostate RT from December 2004 to December 2015. Patients’ signs, symptoms, complications, and treatments are described.

Results: A total of 120 patients were identified with a mean age of 67.8 years; 55.8% (n=67) received external beam radiotherapy (EBRT), 38.3% (n=46) brachytherapy (BT), and 5.8% (n=7) combination RT. The mean time to first complication after RT was 57.7 months (1–219) and number of complications per patient was 5.1±2.2. The most common associated complications were urethral stenosis (n=106, 88.3%), sphincter weakness urinary incontinence (n=55, 45.8%), radiation cystitis (n=61, 50.8%), refractory storage lower urinary tract symptoms (n=106, 88.3%), genitourinary pain (n=28, 23.3%), and prostate necrosis/abscess (n=17, 14.2%). Patients required a mean of 7.4±4.4 treatments over a 33-month period, including urethral dilation/urethrotomy (n= 93, 77.5%), urethroplasty (n=53, 44.2%), transurethral resection (n=52, 43.3%), cystolithopaxy (n=14, 11.7%), artificial urinary sphincter (n=8, 6.7%), and urinary diversion (n=8, 6.7%). Patients with RT combined with other modalities had more complications (6.2 vs. 4.2, p=0.001), higher rates of incontinence (93.8% vs. 29.5%, p=0.001), necrosis (31.3%
vs. 8.0%, p=0.003), erectile dysfunction (84.4% vs. 51.1%, p=0.001), and hematuria (59.4% vs. 36.4%, p=0.04).

Conclusions: Urethral complications related to prostate RT are seldom an isolated problem and require a substantial amount of urological resources and interventions.

Introduction
Prostate cancer is the most common non-cutaneous malignancy and is the 2nd leading cause of cancer deaths amongst men in the U.S.\(^1\) Radiotherapy is one of the most commonly employed modalities for treatment of localized prostate cancer which in turn has subsequently yielded a cumulatively large population of cancer survivors at risk for genitourinary (GU) complications.

The incidence of complications related to prostate cancer treatment have been described in both population-based studies and systematic reviews.\(^2\)-\(^8\) In a population-based study of 32,465 men in the province of Ontario, Nam et al\(^2\) performed an analysis of treatment-related complications, comparing those who had undergone surgery versus RT as primary treatment for their prostate cancer. Those who received RT had a higher 5-year cumulative incidence of admission to hospital.\(^2\) In a collaborative review of the literature, Matta et al\(^3\) described the occurrence of 7 specific pelvic complications secondary to RT including urinary obstruction, urethral stricture, gross hematuria, rectal bleeding, ureteral stricture, rectourethral fistula, and pelvic bone complications.

Urethral complications such as stricture/stenosis, urinary fistula and incontinence cumulatively represent the most common complications of RT as treatment for prostate cancer. For example, \(~3\%\) of men develop urinary obstruction within 2 years of receiving their RT,\(^9\) while acute urinary obstruction may represent up to 25% of acute toxicity-related complications of those receiving combined modality RT.\(^10\) The overall incidence of urethral stenosis has been reported to vary between 1-13%\(^11\) with a pooled incidence of 2.2% in patients receiving EBRT, BT or both at a median follow-up of 4 years.\(^12\) The relative incidence between modalities was 1.5% following EBRT, 1.9% post-BT, and 4.9% in those receiving combined modality RT.

Other complications such as gross hematuria, rectal bleeding due to proctitis, osteomyelitis and secondary malignancies are reported to arise following RT as treatment for prostate cancer. Their incidences, similar to several pelvic complications experienced following RT, tend to increase over time. Incidence rates vary depending on dosage and modality of RT received.\(^13\)-\(^16\)

Despite these studies, the exact clinical scope of complications at a patient-level and their management remains poorly understood. We aimed to describe the clinical
scope and management of urethral complications secondary to RT treatment of prostate cancer. Our hypothesis is that these complications are seldom isolated entities and thus require multiple treatments.

**Methods**

We retrospectively reviewed patients presenting or referred to a single reconstructive urologist for management of Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer (RTOG/EORTC) morbidity score\(^{17}\) grade 4 urethral complication of prostate RT or sphincter-weakness urinary incontinence secondary to prostate RT over an 11-year period (December 2004–December 2015). Inclusion criteria included any patient presenting or referred to a single reconstructive urologist for treatment of grade 4 urethral complications (defined as urethral stricture/stenosis or fistula) or sphincter weakness incontinence secondary to RT as a curative treatment for prostate cancer, whether in the form of EBRT, BT or both. Only patients presenting with urethral stricture/stenoses confirmed to be de novo, post-RT stricture/stenoses were included in the cohort. Patients with radiation treatment for non-prostate cancer-related diagnoses were not included in the analysis.

Patient demographics, presenting signs and symptoms, GU complications, and interventions received as treatment of their symptoms or complications are described. Alberta’s medical record system is province-wide, and thus information related to prior prostate cancer treatment, GU complications related to RT and associated interventions were easily accessible. For patients referred from outside the province, records were obtained from the referring physician.

Urethral stricture was defined as either de novo bulbomembranous strictures, or posterior urethral stenosis that are typical of those associated with radiotherapy. Urinary tract infection (UTI) was defined as a positive urine culture with symptoms consistent with UTI. Radiation cystitis was defined as significant if the patient was symptomatic and required urologic intervention. Acute urinary retention (AUR) was defined as patients requiring emergent urologic intervention. Likewise, hematuria was defined as hematuria requiring urologic intervention. Urologic intervention in these cases were defined as placement of a urethral or suprapubic catheter, cystoscopy, urethral dilation over guidewire, or bladder irrigation. Prostate necrosis or abscess was diagnosed on either cystoscopy or identified on imaging. Refractory storage lower urinary tract symptoms (LUTS) were those patients experiencing persisting storage symptoms despite alleviating obstruction and failing anticholinergic therapy, while ED was patient-reported and refractory to primary care management. Major urethral surgery was defined as requiring urethroplasty, insertion of an artificial urinary sphincter or fistula repair.

Single modality RT group consisted of those who received either EBRT only or BT only while the combined group were those receiving RT combined with other
treatments such as radical prostatectomy, cryotherapy or additional RT. Descriptive statistics, chi-square test and t-tests were used to summarize and compare clinical findings.

Results
A total of 120 patients were identified and included in the analysis with cohort demographics outlined in Table 1. Average patient age was 67.8±8.3 years with a mean time from RT treatment to GU complication of 57.7 months. In terms of RT modality, most patients received EBRT alone (n=67, 55.8%) while 46 patients (38.3%) received BT alone. A total of 7 patients (5.8%) received both EBRT and BT. Twenty-one patients (17.5%) had previously undergone radical prostatectomy.

Patients experienced a mean of 5.1±2.2 complications secondary to their RT (Table 2). The most common associated sign, symptom or complication was urethral stricture/stenosis or refractory storage LUTS persisting despite treatment each found in 106 (88.3%) patients respectively. Other frequently reported complications included ED in 72 (60.0%) patients, radiation cystitis in 61 (50.8%) patients, AUR in 60 (50.0%) patients, sphincter-weakness urinary incontinence in 55 (45.8%) patients and gross hematuria in 51 (42.5%) patients. A total of 28 (23.3%) patients reported GU pain following their RT treatment, while 27 (22.5%) patients reported a history of UTI following RT. Other less common but severe complications included prostate necrosis/abscess in 17 (14.2%) patients, de novo cancer in 7 (5.8%) patients, pubic osteomyelitis/prostatosymphysial fistula in 4 (3.3%) patients.

Patients typically required multiple procedures for treatment of their complications, with a reported mean number of 7.4±4.4 therapeutic procedures received per patient over a mean treatment interval of 33.3 months (Table 3). Fifty-nine patients (49.2%) required major urethral surgery, defined as either urethroplasty, repair of fistula or implantation of an AUS. A total of 93 (77.5%) patients underwent urethral dilation or urethroscopy as part of their treatment. Urethroplasty was required in 53 (44.2%) patients, while 8 (6.7%) patients eventually received surgical treatment of their sphincter-weakness urinary incontinence. Transurethral resection was carried out in 52 patients (43.3%) for a variety of indications, including transurethral resection of prostate, bladder neck, or bladder tumour or clot evacuation. Cystolithopaxy and transurethral extraction of a lower urinary tract stone was required in 14 patients (11.7%). Placement of a suprapubic catheter for potential long-term urinary drainage was required in 16 patients (13.3%) while urinary diversion was performed in 8 patients (6.7%).

Patients undergoing treatment with RT combined with other modalities (Table 4) such as radical prostatectomy, cryotherapy or combination RT had more complications (6.2 vs. 4.7; p=0.001) and were more likely to have incontinence (93.8% vs. 29.5%; p=0.001), necrosis or abscess (31.3% vs. 8.0%; p=0.003), ED (84.4% vs. 51.1%;
Discussion
This retrospective single-surgeon case series of patients presenting for treatment of urethral complications and sphincter-weakness incontinence secondary to RT for prostate cancer treatment describes the clinical scope of high-grade GU complications attributable to pelvic RT treatment and their overall management. The scope of GU complications was broad ranging from urethral stenosis, UTI and refractory LUTS to more devastating complications such as prostatic necrosis, abscess and rectourethral fistula. Multiple complications were the norm, with patients presenting with a mean of 5.1 complications and typically in a delayed fashion at a mean of 57.7 months after treatment. This further confirms that radiation complications typically present late and increase in a time dependent manner. This finding also emphasizes the need for long-term survivorship care in patients undergoing prostate RT.

The typical multiplicity of RT complications poses a significant therapeutic challenge. The sheer spectrum of symptoms and complications renders a standardized treatment approach challenging. The majority of patients (88.3%) had urethral stenosis but coexistent high rates of incontinence (45.8%), ED (60.0%), radiation cystitis (50.8%) and GU pain (23.3%) which make treatment more challenging than simply addressing an isolated urethral stenosis.

This study also simultaneously provides a comprehensive description of the management of RT complications and reveals that patients suffering complications often require multiple therapeutic procedures. The average burden of intervention was high with patients receiving a mean of 7.4 therapeutic procedures as management of their GU complications over 33 months with almost half – 49.2% – requiring major reconstructive urethral surgery defined as urethroplasty, urethral fistula repair or implantation of an AUS. The number of patients undergoing reconstructive surgery would likely be higher, however 38.3% were deemed poor reconstructive candidates due to the multiplicity of their problems, limiting the number of effective treatment options, as determined by the treating reconstructive urologist (KFR). This contributed to the large number of temporizing procedures required over a relatively short treatment period after presenting for treatment. Patients require a broad range of treatments with high rates of endoscopic procedures for stricture, hematuria, lower urinary tract calculi or secondary malignancy. Ultimately 1/5th or more of patients required urinary diversion either in the form of formal urinary diversion or an indwelling suprapubic catheter.

Given the broad scope and therapeutic intensity of RT complications, the incidence with which they occur is of utmost importance. In a population-based study of 32,465 men in the province of Ontario, Nam et al performed a comprehensive analysis of
treatment-related complications, comparing those who had undergone surgery versus RT as primary treatment for their prostate cancer. In their analysis, they focused on complications other than urinary incontinence and erectile function. Of the 32,465 men who received treatment for prostate cancer over the study period, 16,595 received RT. Those who received RT as had a higher 5-year cumulative incidence of admission to hospital (HR 10.8 [95% CI 9.04–12.9]; p<0.0001), requiring a rectal or anal procedure (HR 2.72 [95% CI 2.40–3.08]; p<0.0001), developing a secondary malignancy (HR 2.08 [95% CI 1.48–2.91]; p<0.0001) and requiring an open surgical procedure (HR 3.68 [95% CI 2.16–6.26]; p<0.0001). Almost uniformly the incidence of complications was higher for men undergoing RT when compared to radical prostatectomy. This appears true for other associated complications with an increase in their incidence over time. Studies have suggested an 8-18% 10-year cumulative incidence of gross hematuria,13,14 while the incidence of rectal bleeding has ranged from 4-6% in published studies.15,16 Likewise the rate of fistulae involving the GI tract and risk of developing a secondary malignancy increases with time.2,17

Thus, GU complications following RT as treatment of prostate cancer as described in population-based studies demonstrate an increased rate in the incidence of individual complications when compared to surgery but lack granular data and excludes some of the more common or more devastating complications included in the current analysis such as refractory LUTS, erectile dysfunction, UTI, necrosis and fistulae.3 Moreover, population-based studies are mostly limited to describing the first complication experienced by patients requiring hospitalization2,5 and the scope of complications reported is limited due to the nature of their data set. However, the cumulative incidence of RT complications as described in population-based studies when combined with our current series describing complications at a patient-level reveal the typical scenario is that multiple complications are the norm and patients require frequent and/or intense surgical interventions; this supports the suggestion that RT is possibly a more morbid treatment of prostate cancer when compared to radical prostatectomy in the long-term.

There are some limitations to current study that warrant discussion. Firstly, the RT received is not described in terms of primary versus salvage versus palliative, and other relevant RT parameters are lacking. The patient population therefore, may therefore represent a heterogeneous group in terms of extent of disease and overall dosage of RT received. We suggest however, that including salvage and palliative patients, where typically lower doses of RT would be provided, if anything might underestimate the degree of complications. Additionally, the authors did not include data regarding neoadjuvant, adjuvant or salvage androgen deprivation therapy (ADT). It is possible that ADT may have contributed in some way to particular GU complaints, though we suspect
given the list of treated GU complications, its contribution would have been minimal and largely limited to erectile dysfunction.

The limitations inherent in descriptions of case-series are recognized. The described surgeon is a high-volume reconstructive urologist with a large referral base working in a tertiary academic institution. The patient population presented here may therefore not be representative of community practice and patients may be overly representative of more complex presentations of their GU complications.

Furthermore, there is no way to determine the incidence of complications from the current study as we are reporting on a case series of patients referred with GU complications following prostate cancer treatment with RT. In terms of the complications described, although patients attributed their complications to their RT treatment, the authors acknowledge that some of the described complications including refractory LUTS, AUR and ED can be multifactorial and may not be directly related to RT. Also, with a mean intervention burden of >7 procedures per patient, the authors recognize that some of these interventions may represent re-intervention for the same complication – e.g. multiple TURBTs for de novo bladder cancer. Regardless of re-intervention or not, >7 procedures per patient is meaningful and even if re-interventions were excluded, we would still expect to see a significant burden of intervention for management of these complications.

Despite these limitations, the current study provides a more in-depth analysis of the scope of complications that may be attributable to RT treatment of prostate cancer than we have observed in the literature to date. It builds on previous publications exploring this emerging trend and may further enable patients to make informed decisions regarding therapy for prostate cancer while practitioners may be better equipped to counsel those considering prostate cancer treatment.

Conclusions
Patients receiving RT as treatment of their prostate cancer experience a broad scope of complications, seldom in isolation and often require multiple interventions for their management.
References

1. Siegel RL, Miller KD, Jemel. Cancer statistics, 2019. *CA Cancer J Clin* 2019; 69:7-34.
2. Nam RK, Cheung P, Herschorn S, et al. Incidence of complications other than urinary incontinence or erectile dysfunction after radical prostatectomy or radiotherapy for prostate cancer: a population-based cohort study. *Lancet Oncol* 2014; 15:223-31.
3. Matta R, Chapple CR, Fisch M, et al. Pelvic complications after prostate cancer radiation therapy and their management: An international collaborative narrative review. *Eur Urol* 2019; 75:464-76.
4. Jarosek SL, Virnig BA, Chu H, et al. Propensity-weighted long-term risk of urinary adverse events after prostate cancer surgery, radiation, or both. *Eur Urol* 2015; 67:273-80.
5. Wallis CJD, Herschorn S, Saskin R, et al. Complications after radical prostatectomy or radiotherapy for prostate cancer: results of a population-based, propensity score-matched analysis. *Urology* 2015; 85:621-8.
6. Buda’us L, Bolla M, Bossi A, et al. Functional outcomes and complications following radiation therapy for prostate cancer: a critical analysis of the literature. *Eur Urol* 2012; 61:112-27.
7. Wallis CJ, Mahar A, Cheung P, et al. New rates of interventions to manage complications of modern prostate cancer treatment in older men. *Eur Urol* 2016; 69:933-41.
8. Wallis CJD, Glaser A, Hu JC, et al. Survival and complications following surgery and radiation for localized prostate cancer: an international collaborative review. *Eur Urol* 2018; 73:11-20.
9. Heemsbergen WD, Al-Mamgani A, Witte MG, et al. Urinary obstruction in prostate cancer patients from the Dutch trial (68 Gy vs 78 Gy): relationships with local dose, acute effects, and baseline characteristics. *Int J Radiat Oncol Biol Phys* 2010; 78:19-25.
10. Hsu I-C, Bae K, Shinohara K, et al. Phase II trial of combined high dose-rate brachytherapy and external beam radiotherapy for adenocarcinoma of the prostate: preliminary results of RTOG 0321. *Int J Radiat Oncol Biol Phys* 2010; 78:751-8.
11. Herschorn S, Elliott S, Coburn M, et al. SIU/ICUD consultation on urethral strictures: posterior urethral stenosis after treatment of prostate cancer. *Urology* 2014; 83(3 Suppl): S59-S70.
12. Awad MA, Gaither TW, Osterberg EC, et al. Prostate cancer radiation and urethral strictures: a systematic review and meta-analysis. *Prostate Cancer Prostatic Dis* 2018; 21:168-74.
13. Mathieu R, Arango JDO, Beckendorf V, et al. Nomograms to predict late urinary toxicity after prostate cancer radiotherapy. *World J Urol* 2014; 32:743-51.
14. Sanguineti G, Arcidiacono F, Landoni V, et al. Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study. *Int J Radiat Oncol Biol Phys* 2016; 96:304–12.

15. Wortel RC, Incrocci L, Pos FJ, et al. Late side effects after image guided intensity modulated radiation therapy compared to 3Dconformal radiation therapy for prostate cancer: results from 2 prospective cohorts. *Int J Radiat Oncol Biol Phys* 2016; 95:680-9.

16. Price JG, Stone NN, Stock RG. Predictive factors and management of rectal bleeding side effects following prostate cancer brachytherapy. *Int J Radiat Oncol* 2013; 86:842-7.

17. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). *Int J Radiation Oncology Biol Phys* 1995; 31:1341-6.
### Figures and Tables

**Table 1. Demographics of the patient cohort**

| Factor                                      | n (%)          |
|---------------------------------------------|----------------|
| Number of patients                          | 120            |
| Patient age (years)                         | 67.8±8.3 (49–84) |
| Mean time to complications from radiotherapy (months) | 57.7±54.5 (1–219) |
| Radiotherapy modality                       |                |
| BT                                         | 46 (38.3%)     |
| EBRT                                        | 67 (55.8%)     |
| Combined RT                                 | 7 (5.8%)       |
| Prior radical prostatectomy                 | 21 (17.5%)     |
| Salvage cryotherapy                         | 4 (3.3%)       |
| Mean number of lower tract complications    |                |
| Stenosis length (cm)                        | 5.1±2.2 (1–12) |
| BT: brachytherapy; EBRT: external beam radiotherapy (EBRT); RT: radiotherapy. |

### Table 2. Signs, symptoms, and complications associated with high-grade urethral toxicity after radiotherapy

| Sign, symptom, associated complication | Presenting complaint (n=120) | Reported as secondary sign/symptom/complication |
|----------------------------------------|-------------------------------|-----------------------------------------------|
| Urethral stricture/stenosis            | 97/120 (80.8%)               | 106/120 (88.3%)                              |
| Sphincter weakness urinary incontinence| 9 (7.5%)                     | 55 (45.8%)                                   |
| ED                                     | –                             | 72 (60.0%)                                   |
| GU pain                                | 1 (0.8%)                     | 28 (23.3%)                                   |
| UTI                                    | –                             | 27 (22.5%)                                   |
| Radiation cystitis (symptomatic)       | 8 (6.7%)                     | 61 (50.8%)                                   |
| AUR                                    | –                             | 60 (50.0%)                                   |
| Hematuria                              | –                             | 51 (42.5%)                                   |
| Prostate necrosis/abscess              | –                             | 17 (14.2%)                                   |
| Pubic osteomyelitis/prostatosymphyseal fistula | 2 (1.7%)             | 4 (3.3%)                                     |
| Refractory storage LUTS (independent of stricture treatment) | 2 (1.7%) | 106 (88.3%) |
| Rectourethral fistula                   | 1 (0.8%)                     | 1 (0.8%)                                     |
| De novo cancer (bladder or rectum)      | –                             | 7 (5.8%)                                     |

AUR: acute urinary retention; ED: erectile dysfunction; GU: genitourinary; LUTS: lower urinary tract symptoms; UTI: urinary tract infection.
Table 3. Overall management of radiotherapy complications

| Procedures required by patients                          | n (%)          |
|----------------------------------------------------------|----------------|
| Mean number of therapeutic procedures per patient        | 7.4±4.4 (1–30) |
| Treatment followup (months)                              | 33.3±26.9 (1–116) |
| Procedures required by patients                          |                |
| Major urethral surgery                                   | 59/120 (49.2%) |
| Urethral dilation/urethrotomy                            | 93 (77.5%)     |
| Urethroplasty                                             | 53 (44.2%)     |
| AUS                                                       | 8 (6.7%)       |
| Transurethral resection (prostate, bladder neck, tumor, clot evacuation) | 52 (43.3%) |
| Cystolithopaxy for lower tract calculus                   | 14 (11.7%)     |
| Long-term suprapubic catheter                            | 16 (13.3%)     |
| Urinary diversion                                        | 8 (6.7%)       |
| Deemed poor reconstructive candidate                     | 46 (38.3%)     |

AUS: artificial urinary sphincter.
Table 4. The effect of radiotherapy combined with other treatment modalities (cryotherapy, radical prostatectomy, second radiation)

| Complication                                      | Combined modalities n (%) | Isolated radiotherapy n (%) | p     |
|--------------------------------------------------|---------------------------|-----------------------------|-------|
| Mean number of complications                     | 6.2±2.7                   | 4.7±1.8                     | p=0.001* |
| Urethral stenosis/stricture/contracture          | 25/32 (78.1%)             | 81/88 (92.0%)               | p=0.06 |
| Incontinence                                     | 30 (93.8%)                | 26 (29.5%)                  | p<0.001* |
| De novo cancer (rectal or bladder)               | 3 (9.4%)                  | 4 (4.5%)                    | p=0.38 |
| Pubic osteomyelitis/prostatosymphyseal fistula   | 3 (9.4%)                  | 1 (1.1%)                    | p=0.06 |
| Prostate necrosis/abscess                        | 10 (31.3%)                | 7 (8.0%)                    | p=0.003* |
| Radiation cystitis                               | 21 (65.6%)                | 40 (45.5%)                  | p=0.06 |
| Radiation proctitis                              | 13 (40.6%)                | 14 (15.9%)                  | p=0.006* |
| Erectile dysfunction                             | 27 (84.4%)                | 45 (51.1%)                  | p=0.001* |
| Genitourinary pain                               | 11 (34.4%)                | 17 (19.3%)                  | p=0.09 |
| Urinary tract infection                          | 7 (21.9%)                 | 20 (22.7%)                  | p=1.0  |
| Hematuria                                        | 19 (59.4%)                | 32 (36.4%)                  | p=0.04* |
| Acute urinary retention                          | 16 (50.0%)                | 33 (50.0%)                  | p=1.0  |
| Refractory storage LUTS                          | 25 (78.1%)                | 81 (92.0%)                  | p=0.05* |
| Mean number of procedures                        | 10.1±4.5                  | 7.2±4.3                     | p=0.08 |
| Poor reconstructive candidate                    | 15 (46.9%)                | 31 (35.2%)                  | p=0.25 |

*Statistically significant. LUTS: lower urinary tract symptoms.